NASDAQ : ASND
Ascendis Pharma A/S — Key statistics
Healthcare · Biotechnology · Denmark
Last price 251.27 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 16.50B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 16.43B |
| Enterprise Value | 16.02B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 65.67M |
| Shares Outstanding | 65.67M |
| Shares Change (YoY) | +6.52% |
| Shares Change (QoQ) | +5.89% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 80.65% |
| Float | 65.64M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 18.69 |
| Forward PE | 37.20 |
| PS Ratio | 13.80 |
| Forward PS | 8.58 |
| PB Ratio | 10.06 |
| P/TBV Ratio | 10.08 |
| P/FCF Ratio | 43.91 |
| P/OCF Ratio | 42.10 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 18.98 |
| EV / Sales | 13.45 |
| EV / EBITDA | 53.45 |
| EV / EBIT | 54.44 |
| EV / FCF | 42.81 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.99 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 1.63 |
| Debt / FCF | 1.37 |
| Interest Coverage | 2.01 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 118.78% |
| Return on Assets (ROA) | 9.58% |
| Return on Invested Capital (ROIC) | 12.98% |
| Return on Capital Employed (ROCE) | 14.20% |
| Weighted Average Cost of Capital (WACC) | 7.39% |
| Revenue Per Employee | $1.01M |
| Profits Per Employee | $712,727 |
| Employee Count | 1,189 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.30 |
Taxes
| Measure | Value |
|---|
| Income Tax | -735.66M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.49 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 242.25 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 63.51 |
| Average Volume (20 Days) | 663,292 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.13M |
| Short Previous Month | 3.48M |
| Short % of Shares Out | 5.63% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.27 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.20B |
| Gross Profit | 1.09B |
| Operating Income | 295.51M |
| Pretax Income | 111.78M |
| Net Income | 847.43M |
| EBITDA | 300.99M |
| EBIT | 295.51M |
| Earnings Per Share (EPS) | $13.38 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 927.98M |
| Total Debt | 514.19M |
| Net Cash | 413.78M |
| Net Cash Per Share | $6.30 |
| Equity (Book Value) | 1.64B |
| Book Value Per Share | 24.99 |
| Working Capital | 1.06B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 391.96M |
| Capital Expenditures | -16.14M |
| Depreciation & Amortization | 5.37M |
| Net Borrowing | -33.78M |
| Free Cash Flow | 375.82M |
| FCF Per Share | $5.72 |
Margins
| Measure | Value |
|---|
| Gross Margin | 91.30% |
| Operating Margin | 24.70% |
| Pretax Margin | 9.34% |
| Profit Margin | 70.84% |
| EBITDA Margin | 25.16% |
| EBIT Margin | 24.70% |
| FCF Margin | 32.01% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.52% |
| Shareholder Yield | -6.52% |
| Earnings Yield | 5.35% |
| FCF Yield | 2.28% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $305.37 |
| Price Target Difference | 22.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (3Y) | 51.87% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 8.97 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |